Aryx Therapeutics Stock Today

ARYX
 Stock
  

USD 0.0005  0.00  0.00%   

Market Performance
13 of 100
Odds Of Distress
Over 76
Aryx Therapeutics is trading at 5.0E-4 as of the 8th of August 2022; that is No Change since the beginning of the trading day. The stock's open price was 5.0E-4. Aryx Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Aryx Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of July 2022 and ending today, the 8th of August 2022. Click here to learn more.
CUSIP
043387109
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of November 2007
Category
Healthcare
Classification
Health Care
ISIN
US0433871094
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. Aryx Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 33.46 M outstanding shares of which 89.05 K shares are presently shorted by private and institutional investors with about 0.79 trading days to cover. More on Aryx Therapeutics

Moving against Aryx Therapeutics

0.87AIMAim Immunotech Earnings Call  This WeekPairCorr
0.76ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.73AMPEAmpio Pharmaceuticals Earnings Call  TodayPairCorr
0.66ACSTAcasti Pharma Earnings Call  This WeekPairCorr

Aryx Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Aryx Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aryx Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Aryx Therapeutics is way too risky over 90 days horizon
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics appears to be risky and price may revert if volatility continues
Aryx Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company currently holds 11.57 M in liabilities. Aryx Therapeutics has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 19.72 M. Net Loss for the year was (18.33 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics currently holds about 2.95 M in cash with (20.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Aryx Therapeutics has a very weak financial position based on the latest SEC disclosures
Chairman and CEOPaul Goddard
Fama & French Classification
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Aryx Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Aryx Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Very WeakDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares26.6 M24.7 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted26.6 M24.7 M
Significantly Up
Increasing
Slightly volatile
Total Assets14.1 M13.8 M
Fairly Up
Decreasing
Slightly volatile
Total Liabilities17.6 M17.1 M
Fairly Up
Decreasing
Slightly volatile
Current Assets10.2 M9.9 M
Fairly Up
Decreasing
Slightly volatile
Current Liabilities11.6 M9.8 M
Fairly Up
Increasing
Stable
Total Debt8.8 M8.7 M
Slightly Up
Decreasing
Slightly volatile
Gross Margin0.820.89
Significantly Down
Increasing
Stable
Asset Turnover0.270.33
Significantly Down
Increasing
Stable
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Aryx Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Financial Strength
Aryx Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aryx Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aryx Therapeutics' financial leverage. It provides some insight into what part of Aryx Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Aryx Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Aryx Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Aryx Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 11.57 M in liabilities. Aryx Therapeutics has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(43.39 Million)
Aryx Therapeutics (ARYX) is traded on NASDAQ Exchange in USA. It is located in 6300 Dumbarton Circle and employs 56 people. Aryx Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with current market capitalization of 237.58 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aryx Therapeutics's market, we take the total number of its shares issued and multiply it by Aryx Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Aryx Therapeutics conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 33.46 M outstanding shares of which 89.05 K shares are presently shorted by private and institutional investors with about 0.79 trading days to cover. Aryx Therapeutics currently holds about 2.95 M in cash with (20.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aryx Therapeutics Probability Of Bankruptcy
Ownership
Aryx Therapeutics retains a total of 33.46 Million outstanding shares. Almost 100.0 percent of Aryx Therapeutics outstanding shares are held by regular investors with 0.0 (percent) owned by insiders and only 0.15 % by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Aryx Therapeutics Ownership Details

Aryx Therapeutics Historical Income Statement

Aryx Therapeutics Income Statement is one of the three primary financial statements used for reporting Aryx Therapeutics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Aryx Therapeutics revenue and expense. Aryx Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Aryx Therapeutics Cost of Revenue is fairly stable at the moment as compared to the past year. Aryx Therapeutics reported Cost of Revenue of 266,800 in 2021. Gross Profit is likely to rise to about 18.9 M in 2022, whereas Consolidated Income is likely to drop (41.2 M) in 2022. View More Fundamentals

Aryx Therapeutics Stock Against Markets

Picking the right benchmark for Aryx Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aryx Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aryx Therapeutics is critical whether you are bullish or bearish towards Aryx Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Aryx Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

Aryx Therapeutics Corporate Executives

Elected by the shareholders, the Aryx Therapeutics' board of directors comprises two types of representatives: Aryx Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aryx Therapeutics. The board's role is to monitor Aryx Therapeutics' management team and ensure that shareholders' interests are well served. Aryx Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aryx Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

Invested in Aryx Therapeutics?

You need to understand the risk of investing before taking a position in Aryx Therapeutics. The danger of trading Aryx Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aryx Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aryx Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aryx Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Aryx Therapeutics information on this page should be used as a complementary analysis to other Aryx Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Aryx Therapeutics Stock analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Aryx Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aryx Therapeutics. If investors know Aryx Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aryx Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
237.6 K
Return On Assets
-0.75
The market value of Aryx Therapeutics is measured differently than its book value, which is the value of Aryx Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Aryx Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aryx Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aryx Therapeutics' market value can be influenced by many factors that don't directly affect Aryx Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.